These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 19520609)
1. Activity of DSA against anaerobically adapted Mycobacterium bovis BCG in vitro. Parrish NM; Ko CG; Dick JD Tuberculosis (Edinb); 2009 Jul; 89(4):325-7. PubMed ID: 19520609 [TBL] [Abstract][Full Text] [Related]
2. Resazurin reduction assays for screening of anti-tubercular compounds against dormant and actively growing Mycobacterium tuberculosis, Mycobacterium bovis BCG and Mycobacterium smegmatis. Taneja NK; Tyagi JS J Antimicrob Chemother; 2007 Aug; 60(2):288-93. PubMed ID: 17586560 [TBL] [Abstract][Full Text] [Related]
3. Effect of n-octanesulphonylacetamide (OSA) on ATP and protein expression in Mycobacterium bovis BCG. Parrish NM; Ko CG; Hughes MA; Townsend CA; Dick JD J Antimicrob Chemother; 2004 Oct; 54(4):722-9. PubMed ID: 15355939 [TBL] [Abstract][Full Text] [Related]
4. In vitro activity of the chelating agents nitroxoline and oxine against Mycobacterium bovis BCG. Murugasu-Oei B; Dick T Int J Antimicrob Agents; 2001 Dec; 18(6):579-82. PubMed ID: 11738349 [TBL] [Abstract][Full Text] [Related]
5. Protective effect of beta-glucan against mycobacterium bovis, BCG infection in BALB/c mice. Hetland G; Løvik M; Wiker HG Scand J Immunol; 1998 Jun; 47(6):548-53. PubMed ID: 9652822 [TBL] [Abstract][Full Text] [Related]
6. Bactericidal activity of 2-nitroimidazole against the active replicating stage of Mycobacterium bovis BCG and Mycobacterium tuberculosis with intracellular efficacy in THP-1 macrophages. Khan A; Sarkar S; Sarkar D Int J Antimicrob Agents; 2008 Jul; 32(1):40-5. PubMed ID: 18538548 [TBL] [Abstract][Full Text] [Related]
7. A high-throughput screen to identify inhibitors of ATP homeostasis in non-replicating Mycobacterium tuberculosis. Mak PA; Rao SP; Ping Tan M; Lin X; Chyba J; Tay J; Ng SH; Tan BH; Cherian J; Duraiswamy J; Bifani P; Lim V; Lee BH; Ling Ma N; Beer D; Thayalan P; Kuhen K; Chatterjee A; Supek F; Glynne R; Zheng J; Boshoff HI; Barry CE; Dick T; Pethe K; Camacho LR ACS Chem Biol; 2012 Jul; 7(7):1190-7. PubMed ID: 22500615 [TBL] [Abstract][Full Text] [Related]
8. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. Koul A; Vranckx L; Dendouga N; Balemans W; Van den Wyngaert I; Vergauwen K; Göhlmann HWH; Willebrords R; Poncelet A; Guillemont J; Bald D; Andries K J Biol Chem; 2008 Sep; 283(37):25273-25280. PubMed ID: 18625705 [TBL] [Abstract][Full Text] [Related]
9. Isoniazid Bactericidal Activity Involves Electron Transport Chain Perturbation. Zeng S; Soetaert K; Ravon F; Vandeput M; Bald D; Kauffmann JM; Mathys V; Wattiez R; Fontaine V Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642937 [TBL] [Abstract][Full Text] [Related]
10. A simple whole cell based high throughput screening protocol using Mycobacterium bovis BCG for inhibitors against dormant and active tubercle bacilli. Khan A; Sarkar D J Microbiol Methods; 2008 Apr; 73(1):62-8. PubMed ID: 18328582 [TBL] [Abstract][Full Text] [Related]
11. Loperamide exerts a direct bactericidal effect against M. tuberculosis, M. bovis, M. terrae and M. smegmatis. Barrientos OM; Juárez E; Gonzalez Y; Castro-Villeda DA; Torres M; Guzmán-Beltrán S Lett Appl Microbiol; 2021 Mar; 72(3):351-356. PubMed ID: 33220096 [TBL] [Abstract][Full Text] [Related]
12. Phenotypic changes in mycobacteria grown in oxygen-limited conditions. Gillespie J; Barton LL; Rypka EW J Med Microbiol; 1986 May; 21(3):251-5. PubMed ID: 3084791 [TBL] [Abstract][Full Text] [Related]
13. Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics. Ritz N; Tebruegge M; Connell TG; Sievers A; Robins-Browne R; Curtis N Antimicrob Agents Chemother; 2009 Jan; 53(1):316-8. PubMed ID: 18955515 [TBL] [Abstract][Full Text] [Related]
14. Antituberculous drug susceptibility testing of Mycobacterium bovis BCG strain Montréal. Rousseau P; Dupuis M Can J Microbiol; 1990 Oct; 36(10):735-7. PubMed ID: 2253115 [TBL] [Abstract][Full Text] [Related]
15. Anti-mycobacterial activities of synthetic cationic α-helical peptides and their synergism with rifampicin. Khara JS; Wang Y; Ke XY; Liu S; Newton SM; Langford PR; Yang YY; Ee PL Biomaterials; 2014 Feb; 35(6):2032-8. PubMed ID: 24314557 [TBL] [Abstract][Full Text] [Related]
16. Antimycobacterial activity of UDP-galactopyranose mutase inhibitors. Borrelli S; Zandberg WF; Mohan S; Ko M; Martinez-Gutierrez F; Partha SK; Sanders DA; Av-Gay Y; Pinto BM Int J Antimicrob Agents; 2010 Oct; 36(4):364-8. PubMed ID: 20678902 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Mycobacterium smegmatis and BCG models for the discovery of Mycobacterium tuberculosis inhibitors. Altaf M; Miller CH; Bellows DS; O'Toole R Tuberculosis (Edinb); 2010 Nov; 90(6):333-7. PubMed ID: 20933470 [TBL] [Abstract][Full Text] [Related]
18. In vitro drug susceptibility of Mycobacterium bovis BCG Connaught and Tokyo strains. Shimizu T; Yasumoto K; Tatano Y; Tomioka H; Sato K; Sano C; Kumon H; Monden K J Infect; 2010 Mar; 60(3):248-51. PubMed ID: 20074586 [No Abstract] [Full Text] [Related]
19. Dependence of Mycobacterium bovis BCG on anaerobic nitrate reductase for persistence is tissue specific. Fritz C; Maass S; Kreft A; Bange FC Infect Immun; 2002 Jan; 70(1):286-91. PubMed ID: 11748194 [TBL] [Abstract][Full Text] [Related]
20. In vitro antimycobacterial activity of 5-chloropyrazinamide. Cynamon MH; Speirs RJ; Welch JT Antimicrob Agents Chemother; 1998 Feb; 42(2):462-3. PubMed ID: 9527809 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]